ZNF499 antibody - middle region (ARP30017_P050)
- Known as:
- ZNF499 (anti-) - middle region (ARP30017_P050)
- Catalog number:
- arp30017_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ZNF499 antibody - middle region (ARP30017_P050)
Related genes to: ZNF499 antibody - middle region (ARP30017_P050)
- Gene:
- ZBTB45 NIH gene
- Name:
- zinc finger and BTB domain containing 45
- Previous symbol:
- ZNF499
- Synonyms:
- FLJ14486
- Chromosome:
- 19q13.43
- Locus Type:
- gene with protein product
- Date approved:
- 2003-12-03
- Date modifiied:
- 2014-11-19
Related products to: ZNF499 antibody - middle region (ARP30017_P050)
Related articles to: ZNF499 antibody - middle region (ARP30017_P050)
- Identifying those parameters that could potentially predict the deterioration of metabolically healthy phenotype is a matter of debate. In this field, epigenetics, in particular DNA methylation deserves special attention. - Source: PubMed
Publication date: 2021/09/27
Gutiérrez-Repiso CarolinaLinares-Pineda Teresa MaríaGonzalez-Jimenez AndresAguilar-Lineros FranciscaValdés SergioSoriguer FedericoRojo-Martínez GemmaTinahones Francisco JMorcillo Sonsoles - Understanding the regulatory mechanisms controlling the fate decisions of neural stem cells (NSCs) is a crucial issue to shed new light on mammalian central nervous system (CNS) development in health and disease. We have investigated a possible role for the previously uncharacterized BTB/POZ-domain containing zinc finger factor Zbtb45 in the differentiation of NSCs and postnatal oligodendrocyte precursors. In situ hybridization histochemistry and RT-qPCR analysis revealed that Zbtb45 mRNA was ubiquitously expressed in the developing CNS in mouse embryos at embryonic day (E) 12.5 and 14.5. Zbtb45 mRNA knockdown in embryonic forebrain NSCs by siRNA resulted in a rapid decrease in the expression of oligodendrocyte-characteristic genes after mitogen (FGF2) withdrawal, whereas the expression of astrocyte-associated genes such as CD44 and GFAP increased compared to control. Accordingly, the number of astrocytes was significantly increased seven days after Zbtb45 siRNA delivery to NSCs, in contrast to the numbers of neuronal and oligodendrocyte-like cells. Surprisingly, mRNA knockdown of the Zbtb45-associated factor Med31, a subunit of the Mediator complex, did not result in any detectable effect on NSC differentiation. Similar to NSCs, Zbtb45 mRNA knockdown in oligodendrocyte precursors (CG-4) reduced oligodendrocyte maturation upon mitogen withdrawal associated with down-regulation of the mRNA expression and protein levels of markers for oligodendrocytic differentiation. Zbtb45 mRNA knockdown did not significantly affect proliferation or cell death in any of the cell types. Based on these observations, we propose that Zbtb45 is a novel regulator of glial differentiation. - Source: PubMed
Publication date: 2010/12/15
Södersten ErikLilja TobiasHermanson Ola